EyePoint(NASDAQ) EYPT

Market Cap$1.03B

Since IPO (2008)-59%

5 Year+49%

1 Year+25%

1 Month-7%

$12.25

-4.74%

-0.61Today

After hours$12.26+$0.01 (+0.08%)

EyePoint last closing stock price
Metric	Price	Date
Last close	USD 12.25	2026-07-31

EyePoint stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0.49%	USD 12.19	2026-07-24
1 month	-7.16%	USD 13.20	2026-07-01
3 month	-8.17%	USD 13.34	2026-05-01
Year to date	-32.95%	USD 18.27	2025-12-31
1 year	+24.75%	USD 9.82	2025-07-31
3 year	-3.54%	USD 12.70	2023-08-01
5 year	+49.03%	USD 8.22	2021-07-30
Since inception	-59.31%	USD 31.60	2008-06-11

EyePoint Financials at a Glance

Market Cap

$1.03B

Revenue (TTM)

$7.62M

Net Income (TTM)

-$271.60M

EPS (TTM)

-$3.50

P/E Ratio

-3.50

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$12.25

Volume

1,711,475.698

Open

$12.81

Price

$12.25

Volume

1,711,475.698

Open

$12.81

Previous Close

$12.25

Daily Range

$12.04 - $12.83

52-Week Range

$9.40 - $19.11

Estimated Earnings Date

Aug 5, 2026

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$12.25

Volume

1,711,475.698

Open

$12.81

Previous Close

$12.25

Daily Range

$12.04 - $12.83

52-Week Range

$9.40 - $19.11

Estimated Earnings Date

Aug 5, 2026

EYPT News

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

Jonathan PoncianoMar 15, 2026

Page 1

EYPT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About EyePoint

EyePoint makes treatments for serious diseases affecting the back of the eye. These medicines use technology to release drugs slowly over many months. This helps patients avoid frequent and painful shots in the eye.

What Does EyePoint Build?

DURAVYU: Investigational treatment for wet age-related macular degeneration, a condition where leaky blood vessels cause vision loss.
YUTIQ: Three-year implant for chronic eye inflammation; US commercial rights were licensed to ANI Pharmaceuticals in 2023.
ILUVIEN: Sustained-release insert for diabetic macular edema, which is eye swelling caused by high blood sugar.
DEXYCU: Medicine applied during surgery to treat inflammation after a patient receives a new cataract lens.
EYP-2301: Early-stage program testing a new chemical method to stabilize blood vessels in the eye.

Strategic Moves and Partnerships

Licensed US rights for YUTIQ to ANI Pharmaceuticals in May 2023 for $82.5 million.
Opened a 41,000 square foot commercial manufacturing plant in Northbridge, Massachusetts in October 2024.
Purchased a portfolio of patents and molecules from Aerpio Pharmaceuticals in 2021 to expand its research.
Formed an alliance with Ocumension Therapeutics to develop and sell eye treatments in China and Southeast Asia.

The Sustained Release Edge

EyePoint uses its Durasert technology to turn liquid drugs into tiny, solid inserts. These inserts provide a steady dose of medicine for months or years to reduce the need for repeat clinic visits.

Recent Financial Performance

Revenue fell to $620,000 in Q4 2025, down 94.6% from $11.6 million in Q4 2024.
Net loss worsened to $67.6 million in Q4 2025, deepening by 63.3% from the previous year.
Free cash flow was negative $66 million in Q4 2025, worsening 82.2% year-over-year.
Market capitalization reached $1.5 billion in Q4 2025, up 215.4% from $480.9 million in Q4 2024.

Bottom Line

EyePoint has transitioned from a commercial product seller to a clinical-stage developer focused on long-acting retinal therapies. Its growth now depends on the successful outcome of large-scale trials for its lead drug candidate.

AI Generated • May 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

214

CEO

Jay S. Duker, MD

Website

www.eyepointpharma.com

Headquarters

Watertown, MA 02472, US

EYPT Financials

Key Financial Metrics (TTM)

Gross Margin

76.51%

Operating Margin

-3700.89%

Net Income Margin

-3566.63%

Return on Equity

-110.54%

Return on Capital

-74.01%

Return on Assets

-94.23%

Earnings Yield

-28.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.03B

Shares Outstanding

83.84M

Volume

1.71M

Avg. Volume

1.28M

Financials (TTM)

Gross Profit

$5.83M

Operating Income

-$281.82M

EBITDA

-$260.06M

Operating Cash Flow

-$267.54M

Capital Expenditure

-$4.00M

Free Cash Flow

-$271.54M

Cash & ST Invst.

$222.55M

Total Debt

$22.31M

EyePoint Performance Analysis

EyePoint annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 41,404,000	12.1%
2023	2023-12-31	USD 46,018,000	11.1%
2024	2024-12-31	USD 43,273,000	-6.0%
2025	2025-12-31	USD 31,371,000	-27.5%

EyePoint sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-78.2%
Q3	2025-09-30	-81.9%
Q4	2025-12-31	-35.8%
Q1	2026-03-31	12.3%

EyePoint annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.74	34.9%
2023	2023-12-31	USD -1.82	-33.6%
2024	2024-12-31	USD -2.32	27.7%
2025	2025-12-31	USD -3.17	36.2%

EyePoint sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-30.8%
Q3	2025-09-30	N/A
Q4	2025-12-31	4.7%
Q1	2026-03-31	-22.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$696.00K

-97.2%

Gross Profit

$168.00K

-99.3%

Gross Margin

24.14%

N/A

Market Cap

$1.03B

N/A

Market Cap/Employee

$4.80M

N/A

Employees

214

N/A

Net Income

-$84.83M

-87.7%

EBITDA

-$84.25M

-88.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$222.55M

-30.1%

Total Debt

$22.31M

-7.3%

Accounts Receivable

$1.16M

+161.8%

Inventory

$1.25M

-41.3%

Long Term Debt

$20.23M

-9.3%

Short Term Debt

$2.08M

+17.9%

Return on Assets

-94.23%

N/A

Return on Invested Capital

-1.12%

N/A

Free Cash Flow

-$81.55M

-52.7%

Operating Cash Flow

-$80.55M

-51.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SVRASavara Inc.

SVRASavara Inc.$5.46-1.44%

KURAKura Oncology, Inc.

KURAKura Oncology, Inc.$9.01-3.22%

BCAXBicara Therapeutics Inc. Common Stock

BCAXBicara Therapeutics Inc. Common Stock$27.10+3.16%

PRMEPrime Medicine, Inc.

PRMEPrime Medicine, Inc.$2.92-3.31%

PROKProKidney Corp.

PROKProKidney Corp.$1.54-2.53%

SEPNSepterna Inc

SEPNSepterna Inc$34.45-2.08%

RZLTRezolute, Inc.

RZLTRezolute, Inc.$4.72-3.28%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About EYPT

What is the current price of EyePoint?

EyePoint is trading at $12.25 per share.

What is the 52-week range for EyePoint?

Over the past 52 weeks, EyePoint has traded between $9.40 and $19.11.

How much debt does EyePoint have?

As of the most recent reporting period, EyePoint reported total debt of $22.31M.

How much cash does EyePoint have on hand?

EyePoint reported $77.71M in cash and cash equivalents in its most recent financial results.

What is EyePoint’s dividend yield?

EyePoint does not currently have a dividend yield.

EyePoint(NASDAQ) EYPT

EyePoint Financials at a Glance

EYPT News

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

EyePoint (EYPT) Q2 Revenue Drops 44%

Why Shares of EyePoint Pharmaceuticals Were Rising Monday

Why EyePoint Pharmaceuticals Shot 31% Higher Today

Why EyePoint Pharmaceuticals Is Cratering Today

3 Top Small-Cap Stocks to Buy in October

3 Top Biotech Stocks to Buy in September

Keep Your Eye on These 4 Healthcare Stocks

EYPT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About EyePoint

What Does EyePoint Build?

Strategic Moves and Partnerships

The Sustained Release Edge

Recent Financial Performance

Bottom Line

EYPT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

EyePoint Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EYPT

What is the current price of EyePoint?

What is the 52-week range for EyePoint?

How much debt does EyePoint have?

How much cash does EyePoint have on hand?

What is EyePoint’s dividend yield?

Premium Investing Services